Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
It is essential to improve therapies for controlling excessive bleeding in patients with haemorrhagic disorders. As activated blood platelets mediate the primary response to vascular injury, we hypothesize that storage of coagulation Factor VIII within platelets may provide a locally inducible treatment to maintain haemostasis for haemophilia A. Here we show that haematopoietic stem cell gene therapy can prevent the occurrence of severe bleeding episodes in dogs with haemophilia A for at least 2.5 years after transplantation. We employ a clinically relevant strategy based on a lentiviral vector encoding the ITGA2B gene promoter, which drives platelet-specific expression of human FVIII permitting storage and release of FVIII from activated platelets. One animal receives a hybrid molecule of FVIII fused to the von Willebrand Factor propeptide-D2 domain that traffics FVIII more effectively into α-granules. The absence of inhibitory antibodies to platelet-derived FVIII indicates that this approach may have benefit in patients who reject FVIII replacement therapies. Thus, platelet FVIII may provide effective long-term control of bleeding in patients with haemophilia A.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Langdell, R. D., Wagner, R. H., & Brinkhous, K. M. (1953) · PubMed · Cited by 852
Sanders, J., Hawley, J., Levy, W., Gooley, T., Buckner, C., Deeg, H., Doney, K., Storb, R., Sullivan, K., Witherspoon, R., et al. (1996) · Blood · doi:10.1182/blood.v87.7.3045.bloodjournal8773045 · Cited by 722
Wiznerowicz, M., & Trono, D. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8957-8951.2003 · Cited by 701
Kitazawa, T., Igawa, T., Sampei, Z., Muto, A., Kojima, T., Soeda, T., Yoshihashi, K., Okuyama-Nishida, Y., Saito, H., Tsunoda, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2942 · Cited by 507
Megakaryocytic and erythrocytic lineages share specific transcription factors
Romeo, P.-H., Prandini, M.-H., Joulin, V., Mignotte, V., Prenant, M., Vainchenker, W., Marguerie, G., & Uzan, G. (1990) · Nature · doi:10.1038/344447a0 · Cited by 418
Specific roles for platelet surface glycoproteins in platelet function
NURDEN, A. T., & CAEN, J. P. (1975) · Nature · doi:10.1038/255720a0 · Cited by 405
Self-citationSynthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells.
Kaufman, R. J., Wasley, L. C., & Dorner, A. J. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68793-9 · Cited by 380
Berntorp, E., & Shapiro, A. D. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61139-2 · Cited by 335
Beyond Clotting: The Powers of Platelets
Leslie, M. (2010) · Science · doi:10.1126/science.328.5978.562 · Cited by 332
Cited by
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Murine coagulation factor VIII is synthesized in endothelial cells
Everett, L. A., Cleuren, A. C. A., Khoriaty, R. N., & Ginsburg, D. (2014) · Blood · doi:10.1182/blood-2014-02-554501 · Cited by 190
Adeno-Associated Virus Gene Therapy for Hemophilia
Samelson‐Jones, B. J., & George, L. A. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-033013 · Cited by 150
Novel approaches to hemophilia therapy: successes and challenges
Arruda, V. R., Doshi, B. S., & Samelson‐Jones, B. J. (2017) · Blood · doi:10.1182/blood-2017-08-742312 · Cited by 124
von Willebrand factor propeptide: biology and clinical utility
Haberichter, S. L. (2015) · Blood · doi:10.1182/blood-2015-04-512731 · Cited by 99
Self-citationGene therapy for hemophilia: what does the future hold?
Doshi, B. S., & Arruda, V. R. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718791933 · Cited by 97
A Molecular Revolution in the Treatment of Hemophilia
Butterfield, J. S. S., Hege, K. M., Herzog, R. W., & Kaczmarek, R. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.006 · Cited by 94
Lange, A. M., Altynova, E. S., Nguyen, G. N., & Sabatino, D. E. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.64 · Cited by 78
Current status of haemophilia gene therapy
High, K. H., Nathwani, A., Spencer, T., & Lillicrap, D. (2014) · Haemophilia · doi:10.1111/hae.12411 · Cited by 73
Development of gene transfer for induction of antigen-specific tolerance
Sack, B. K., Herzog, R. W., Terhorst, C., & Markusic, D. M. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.13 · Cited by 70
Gene therapy for immune tolerance induction in hemophilia with inhibitors
Arruda, V. R., & Samelson‐Jones, B. J. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13331 · Cited by 69
Targeting Antigen-Specific B Cells Using Antigen-Expressing Transduced Regulatory T Cells
Zhang, A.-H., Yoon, J., Kim, Y. C., & Scott, D. W. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701800 · Cited by 63
Hemophilia Gene Therapy: Approaching the First Licensed Product
Batty, P. A., & Lillicrap, D. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000540 · Cited by 65
Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy
Samelson-Jones, B. J., & Arruda, V. R. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.007 · Cited by 58
Herzog, R. W. (2015) · Frontiers in Bioscience · doi:10.2741/4324 · Cited by 55
“This approach has also proven effective in canine models of hemophilia, and LV-transduced human cord blood cells correct the bleeding phenotype when transplanted into immunodeficient hemophilic mice (315, 316).”
BackgroundSwieringa, F., Kuijpers, M. J. E., Lamers, M. M. E., van der Meijden, P. E. J., & Heemskerk, J. W. M. (2015) · Haematologica · doi:10.3324/haematol.2014.116863 · Cited by 59
In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs
Wu, Y. C., Hu, Z., Li, Z., Pang, J., Feng, M., Hu, X., Wang, X., Linpeng, S., Liu, B., Chen, F., et al. (2016) · Scientific Reports · doi:10.1038/srep18865 · Cited by 60
Nguyen, G. N., George, L. A., Siner, J. I., Davidson, R. J., Zander, C. B., Zheng, X. L., Arruda, V. R., Camire, R. M., & Sabatino, D. E. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13543 · Cited by 50
Roctavian gene therapy for hemophilia A
Samelson‐Jones, B. J., Small, J. C., & George, L. A. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011847 · Cited by 58
Hemophilia Gene Therapy: The End of the Beginning?
Wolf, D. D., Singh, K., Chuah, M., & VandenDriessche, T. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.112 · Cited by 50
“12 Long-term expression of the clotting factors is expected by virtue of the stable genomic integration of the therapeutic transgenes in bona fide HSPCs.”
Contemporary Animal Models For Human Gene Therapy Applications
Gopinath, C., Nathar, T. J., Ghosh, A., Hickstein, D. D., & Nelson, E. J. R. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150929110424 · Cited by 49
“In a few recent gene therapy studies, dogs have also been used as models for haemophilia [63, 64], ocular disorders [65, 66] and cardiovascular diseases [67, 68].”
BackgroundRecent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives
Chernyi, N., Gavrilova, D., Saruhanyan, M., Oloruntimehin, E. S., Karabelsky, A. V., Bezsonov, E. E., & Malogolovkin, A. S. (2024) · Biomolecules · doi:10.3390/biom14070854 · Cited by 48
“Alternative microRNA (miR) medication was created in a study that successfully restored FIX activity in animal models of hemophilia B and stabilized transgene expression in the liver without showing any signs of genotoxicity [96].”
Nichols, T. C., Hough, C. A., Agersø, H., Ezban, M., & Lillicrap, D. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13301 · Cited by 45
Self-citationMolecular basis of clot retraction and its role in wound healing
Nurden, A. T. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.08.010 · Cited by 44
Self-citationPlatelet-Targeted Gene Therapy for Hemophilia
Shi, Q. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.011 · Cited by 38
“To further evaluate the efficacy of platelet gene therapy of hemophilia A, Du et al.(32) applied a 2bF8 gene therapy protocol to hemophilia A dogs.”
MethodSelf-citationGene therapy for hemophilia: past, present and future
George, L. A., & Fogarty, P. F. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.10.002 · Cited by 37
Schroeder, J. A., Chen, Y., Fang, J., Wilcox, D. A., & Shi, Q. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12633 · Cited by 36
Self-citationHaemophilia gene therapy: Progress and challenges
Lhériteau, E., Davidoff, A. M., & Nathwani, A. C. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.03.002 · Cited by 38
“This is in part due to the ability of gene-modified platelet to release the transgenic FVIII locally at the site of injury from stores in the alpha granules following platelet activation [31–33].”
BackgroundPipe, S. W. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26865 · Cited by 37
Current animal models of hemophilia: the state of the art
Yen, C., Fan, M., Yang, Y., Chou, S., Yu, I., & Lin, S. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0106-0 · Cited by 42
“Hemophilia A dogs have been used extensively in preclinical trials of human FVIII protein products as well as in studies on the safety and efficacy of adeno-associated viral (AAV) vector-conducted gene therapy [9], in testing the gene therapy of platelet-specific expression of human FVIII [10], and have provided promi…”
MethodObstacles and future of gene therapy for hemophilia
Arruda, V. R., & Samelson-Jones, B. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1069179 · Cited by 33
“However, additional studies in large animal hemophilia models, such as dogs, are needed to determine the safety and efficacy of this approach (the first such study of HA dogs was recently reported, as discussed below in Section 6 [81]).”
BackgroundInnovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
Sherman, A., Biswas, M., & Herzog, R. W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01604 · Cited by 33
“Similarly, LV-modified autologous canine megakaryocytes (precursors of platelets) expressing FVIII in α-granules prevented bleeding episodes in hemophilia A dogs (137).”
BackgroundNew approaches to gene and cell therapy for hemophilia
Ohmori, T., Mizukami, H., Ozawa, K., Sakata, Y., & Nishimura, S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12926 · Cited by 30
Generation and manipulation of human iPSC-derived platelets
Sugimoto, N., & Eto, K. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03749-8 · Cited by 30
Gene therapy in an era of emerging treatment options for hemophilia B
Monahan, P. E. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12957 · Cited by 31
“Adapting an approach that has demonstrated phenotypic correction in large animal models of hemophilia A and Glanzmann Thrombasthenia [50], a LV construct expressing human factor IX under the control of the platelet-specific glycoprotein IIb gene (aIIb) promoter was used to transduce FIX / mouse hematopoietic stem cell…”
MethodHemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche, T., & Chuah, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.116 · Cited by 32
“38,58,59 As activated blood platelets mediate the primary response to vascular injury, storage of FVIII within platelets may provide a locally inducible treatment to maintain hemostasis for hemophilia A. Remarkably, phenotypic correction of the bleeding disease in hemophilia A mice could even be…”
Gene therapy for hemophilia: Progress to date and challenges moving forward
Gollomp, K. L., Doshi, B. S., & Arruda, V. R. (2019) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2019.08.012 · Cited by 33
Ercan, H., Mauracher, L., Grilz, E., Hell, L., Hellinger, R., Schmid, J. A., Moik, F., Ay, C., Pabinger, I., & Zellner, M. (2021) · Cancers · doi:10.3390/cancers13092260 · Cited by 45
Pang, J., Wu, Y. C., Li, Z., Hu, Z., Wang, X., Hu, X., Wang, X., Liu, X., Zhou, M., Liu, B., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.02.083 · Cited by 32
An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs
Sun, J., Shao, W., Chen, X., Merricks, E. P., Wimsey, L., Abajas, Y. L., Niemeyer, G. P., Lothrop, C. D., Monahan, P. E., Samulski, R. J., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.07.011 · Cited by 30
“10 Septe were expressed as total photon flux (photons per second), which has been used widely in studies.(51,52)”
MethodSelf-citationWFH State‐of‐the‐art paper 2020: In vivo lentiviral vector gene therapy for haemophilia
Cantore, A., & Naldini, L. (2020) · Haemophilia · doi:10.1111/hae.14056 · Cited by 33
Progress and challenges in the development of a cell‐based therapy for hemophilia A
Fomin, M. E., Togarrati, P. P., & Muench, M. O. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12750 · Cited by 32
Genetically engineered transfusable platelets using mRNA lipid nanoparticles
Leung, J., Strong, C., Badior, K. E., Robertson, M. K., Wu, X., Meledeo, M. A., Kang, E., Paul, M., Sato, Y., Harashima, H., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi0508 · Cited by 33
Chen, Y., Schroeder, J. A., Chen, J., Luo, X., Baumgartner, C. K., Montgomery, R. R., Hu, J., & Shi, Q. (2015) · Blood · doi:10.1182/blood-2015-08-662916 · Cited by 26
Self-citationGene Therapy for Inherited Bleeding Disorders
Arruda, V. R., Weber, J., & Samelson‐Jones, B. J. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1722862 · Cited by 25
Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications
Luo, L., Zheng, Q., Chen, Z., Huang, M., Fu, L., Hu, J., Shi, Q., & Chen, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019275 · Cited by 31
Self-citationNew directions to develop therapies for people with hemophilia
Gogia, P., Tarantino, M. D., Schramm, W., & Aledort, L. M. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2184341 · Cited by 25
“Multiple preclinical studies have supported the transduction of hematopoietic stem cells ex vivo with lentiviruses to generate genetically modified platelets to control bleeding in patients with severe HA with inhibitors [156,157].”
BackgroundHaemophilia gene therapy: From trailblazer to gamechanger
Evens, H., Chuah, M., & VandenDriessche, T. (2018) · Haemophilia · doi:10.1111/hae.13494 · Cited by 26
Hemophilia gene therapy: ushering in a new treatment paradigm?
George, L. A. (2021) · Hematology · doi:10.1182/hematology.2021000254 · Cited by 25
Arruda, V. R. (2015) · Haematologica · doi:10.3324/haematol.2015.129858 · Cited by 26
“clinical translation of promising preclinical studies utilizing such gene transfer strategies in small and large animal models is, in fact, more tangible.(11) Because the relative contribution of”
BackgroundGreene, T. K., Lyde, R. B., Bailey, S., Lambert, M. P., Zhai, L., Sabatino, D. E., Camire, R. M., Arruda, V. R., & Poncz, M. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12749 · Cited by 23
Kolibaba, K. S., Sterchele, J. A., Joshi, A. D., Forsyth, M., Alwon, E., Beygi, H., & Kennealey, G. T. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620713478629 · Cited by 23
Monahan, P. E. (2015) · Hematology · doi:10.1182/asheducation-2015.1.33 · Cited by 24
Platelets loaded with liposome‐encapsulated thrombin have increased coagulability
Chan, V., Sarkari, M., Sunderland, R., John, A. E. S., White, N. J., & Kastrup, C. J. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14006 · Cited by 22
Rose, M. D., Gao, K., Cortez-Toledo, E., Agu, E., Hyllen, A. A., Conroy, K. L., Pan, G., Nolta, J. A., Wang, A., & Zhou, P. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0261 · Cited by 22
Shi, Q., Schroeder, J. A., Kuether, E. L., & Montgomery, R. R. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13001 · Cited by 21
Self-citationBaumgartner, C. K., Mattson, J. G., Weiler-Guettler, H., Shi, Q., & Montgomery, R. R. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13436 · Cited by 21
Self-citationGuest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY
Doshi, B. S., Arruda, V. R., & Arruda, V. R. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2020.069 · Cited by 25
Valentino, L. A., Ozelo, M. C., Herzog, R. W., Key, N. S., Pishko, A. M., Ragni, M. V., Samelson‐Jones, B. J., & Lillicrap, D. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.05.011 · Cited by 21
Megakaryocyte- and megakaryocyte precursor–related gene therapies
Wilcox, D. A. (2016) · Blood · doi:10.1182/blood-2015-07-607937 · Cited by 23
“Ectopic delivery of coagulation factors from platelets Hemophilia A is a severely debilitating and deadly hemorrhagic disorder (incidence 1:5000 males) linked to molecular genetic defects in the plasma protein, coagulation FVIII.49,50 Plasma-derived and recombinant factor concentrates are currently available from nume…”
BackgroundInfluentialSelf-citationChai, Z., Zhang, X., Dobbins, A. L., Samulski, R. J., Merricks, E. P., Nichols, T. C., & Li, C. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.083 · Cited by 19
Self-citationTargeting transgenic proteins to alpha granules for platelet-directed gene therapy
Woods, V. M. A., Latorre-Rey, L. J., Schenk, F., Rommel, M. G. E., Thomas, M., & Modlich, U. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.12.038 · Cited by 17
“A strategy for loading proteins to aGs has been explored by fusing FVIII to the D2 domain of the vWF propeptide.(15) This domain was shown to be responsible for the sorting and retention of vWF in aGs.”
MethodPlatelets and hemophilia: A review of the literature
Riedl, J., Ay, C., & Pabinger, I. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.05.013 · Cited by 19
Strong, C., Leung, J., Kang, E., Badior, K. E., Robertson, M. K., Pereyra, N., Rowe, E. M., Wietrzny, A., Ma, B., Noronha, Z., et al. (2024) · Blood · doi:10.1182/blood.2024024405 · Cited by 19
Platelet-Targeted Gene Therapy for Hemophilia A with Inhibitor History
Eapen, M., Malec, L. M., Armant, M. A., Johnson, B. D., Shi, Q., Xu, H., Du, L. M., Jerkins, J. H., Duffy, L., Bushman, F. D., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2415164 · Cited by 16
Self-citationDangerous liaisons: cooperation between Pbx3, Meis1 and Hoxa9 in leukemia
Thorne, R., & Milne, T. A. (2015) · Haematologica · doi:10.3324/haematol.2015.129932 · Cited by 16
Replacing bad (F)actors: hemophilia
Doering, C. B., & Spencer, H. T. (2014) · Hematology · doi:10.1182/asheducation-2014.1.461 · Cited by 15
Platelet‐delivered therapeutics
Lyde, R. B., Sabatino, D. E., Sullivan, S. K., & Poncz, M. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12938 · Cited by 16
Baumgartner, C. K., Zhang, G., Kuether, E. L., Weiler-Guettler, H., Shi, Q., & Montgomery, R. R. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13169 · Cited by 14
Self-citationZhao, X., Han, J., Zhou, L., Zhao, J., Huang, M., Wang, Y., Kou, J., Kou, Y., & Jin, J. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.12.003 · Cited by 14
Platelet-targeted gene therapy induces immune tolerance in hemophilia and beyond
Kumar, S., Schroeder, J. A., & Shi, Q. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.07.025 · Cited by 13
Self-citationEscape or Fight: Inhibitors in Hemophilia A
Merlin, S., & Follenzi, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00476 · Cited by 14
“For example, megakaryocyte-restricted FVIII expression using a lentiviral vector containing the integrin subunit αIIb (ITGA2B) promoter (2bF8) was able to ensure sustained long-term correction of the bleeding phenotype in HA mice (58, 97, 98) and dogs (99) without formation of antiFVIII antibodies.”
BackgroundProteomic profiling of the thrombin-activated canine platelet secretome (CAPS)
Cremer, S. E., Catalfamo, J. L., Goggs, R. A. N., Seemann, S. E., Kristensen, A. T., & Brooks, M. B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224891 · Cited by 12
“Dogs with single-gene defects that parallel human hereditary disease have moreover been used to develop and evaluate the efficacy of novel treatments, including platelet-targeted gene therapy [13].”
BackgroundShi, Q., Mattson, J. G., Fahs, S. A., Geurts, A. M., Weiler-Guettler, H., & Montgomery, R. R. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000944 · Cited by 12
“been further proven in a canine HA noninhibitor model.(18) Although these models are informative, neither the canine nor mouse model entirely recapitulates human disease because (1) neither HA mice nor dogs exhibit the high-frequency spontaneous bleeding seen in patients with severe HA and (2) canine platelets do not…”
BackgroundSelf-citationMinno, G. D., Castaman, G., CRISTOFARO, R. D., Brunetti‐Pierri, N., Pastore, L., Castaldo, G., Trama, U., & Minno, M. N. D. D. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101011 · Cited by 12
Targeting expression to megakaryocytes and platelets by lineage‐specific lentiviral vectors
Latorre-Rey, L. J., Wintterle, S., Dütting, S., Kohlscheen, S., Abel, T., Schenk, F., Wingert, S., Rieger, M. A., Nieswandt, B., Heinz, N., et al. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13582 · Cited by 12
Cai, Y., & Shi, Q. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00964 · Cited by 8
“Using a large animal model, hemophilia A dogs, Du and coworkers demonstrated that 2bF8 lentivirus-mediated HSC transduction followed by transplantation improved hemostasis in hemophilia A dogs and animals were well-tolerized to 2bF8 lentivirus-introduced neoprotein with no detectable inhibitor development in treated a…”
BackgroundSelf-citationGene Therapy for Hemophilia A: Where We Stand
Zhou, M., Hu, Z., Zhang, C., Wu, L., Li, Z., & Liang, D. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200806110849 · Cited by 9
Berdel, W. E., Harrach, S., Brand, C., Brömmel, K., Berdel, A. F., Hintelmann, H., Schliemann, C., & Schwöppe, C. (2020) · Cancers · doi:10.3390/cancers12123536 · Cited by 7
Programming megakaryocytes to produce engineered platelets for delivering non-native proteins
Islam, F., Javdan, S. B., Lewis, M. R., Craig, J. D., Wu, H., & Deans, T. L. (2025) · Communications Biology · doi:10.1038/s42003-025-08017-8 · Cited by 10
“Additionally, a study demonstrated that fi lledwithhumanFVIII,aproteinthatplaysakeyrolein clotting and hemostasis 39 .”
Zhao, J., Zhou, M., Wang, Z., Wu, L., Hu, Z., & Liang, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020623 · Cited by 6
Molecular therapeutics of hemophilia A and B
Gong, J., Wang, H., & Chang, L. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2075339 · Cited by 6
Gene therapy: Genie in a vector
Gould, J. (2014) · Nature · doi:10.1038/515s160a · Cited by 6
Kochat, V., Kanjirakkuzhiyil, S., Baligar, P., Nagarajan, P., & Mukhopadhyay, A. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0119-9 · Cited by 6
“correction of HA in animal models [4–6], although the outcome of the phase I clinical trial was not conclusive; there was a gradual loss of its potency because of the”
Gong, J., Yang, R., Zhou, M. Q., & Chang, L. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00680-z · Cited by 5
Larsen, M. S., Juul, R. V., Zintner, S. M., Kristensen, A. T., Margaritis, P., Kjelgaard-Hansen, M. J., Wiinberg, B., Simonsson, U. S. H., & Kreilgaard, M. (2019) · Haemophilia · doi:10.1111/hae.13899 · Cited by 4
Treatment of a Hemophilia B Mouse Model with Platelet-Targeted Expression of Factor IX Padua
Li, B., Wu, Z., Xu, W., Han, W., Liu, J., Wang, D., & Zhang, G. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.309 · Cited by 5
“15,38,39 These studies suggest that this platelet-targeted gene therapy strategy could be effective in the clinical treatment of hemophilia.”
Emerging gene therapies for enhancing the hemostatic potential of platelets
Leung, J., Cau, M. F., & Kastrup, C. J. (2021) · Transfusion · doi:10.1111/trf.16519 · Cited by 5
Shao, W., Sun, J., Chen, X., Dobbins, A. L., Merricks, E. P., Samulski, R. J., Nichols, T. C., & Li, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.815317 · Cited by 4
Self-citationKoukouritaki, S. B., Thinn, A. M. M., Ashworth, K. J., Fang, J., Slater, H. S., Du, L. M., Nguyen, H. T. T., Pillois, X., Nurden, A. T., Ng, C. J., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009495 · Cited by 4
“Immunofluorescent confocal microscopy Human platelets were fixed, permeabilized, blocked, incubated with antifibrinogen 1Ab and Alexa488-2Ab and visualized on a confocal microscope as previously described (supplemental Method 3).(29)”
MethodSelf-citationUnderstanding the Clotting Cascade, Regulators, and Clinical Modulators of Coagulation
Pilli, V. S. S. (2018) · InTech eBooks · doi:10.5772/intechopen.75141 · Cited by 3
“Bleeding events were stopped in the hemophilic dogs after transfusing them with genetically altered platelets [53].”
BackgroundSAKUMA, S., Okamoto, M., Matsushita, N., Ukawa, M., Tomono, T., Kawamoto, K., Ikeda, T., & Sakuma, S. (2022) · Journal of Veterinary Medical Science · doi:10.1292/jvms.21-0647 · Cited by 4
[Research advances on gene therapy for hemophilia A].
Li, X., Zhang, J., Zhang, L., Cheng, T., & Zhang, X. (2015) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2015.07.022 · Cited by 3
“HSC/巨核细胞异位表达FVIII:近 30%的HA患者在长 期输注FVIII后会产生抑制物[19]。虽然通过免疫调控方法可 以适当控制抑制物,但尚未完善,而且治疗费用昂贵。 近年来,Wilcox等开创了一种新的治疗方法:利用HSC 基因治疗方法,使FVIII在巨核细胞和血小板中异位表达。他 们通过一系列体外实验表明,异源性FVIII可在巨核细胞系中 表达和储存,并且只有激动剂刺激后,FVIII才能释放[20-21]。这 一结果后来在HA小鼠体内实验中得到证实:血浆中FVIII处 于低水平,而血小板FVIII处于高水平,血小板在损伤部位活 化后释放储存于α颗粒中的FVIII,使小鼠在实验性表皮出血 试验中存活。更重要的是,即使HA…”
BackgroundLiras, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1029451 · Cited by 3
“When this strategy is applied, it must be remembered that even if transgene expression is lengthened, it will always be transient [29], which contrasts to the results obtained by Du [30] in a series of dogs where the use of nonoptimized lentiviral vectors in platelet precursors produced a length of factor VIII express…”
ResultPlatelets and coagulation: partners in haemostasis
Swieringa, F. (2016) · Research Publications (Maastricht University) · doi:10.26481/dis.20160331fs · Cited by 2
Gene Therapy for Platelet Disorders
Wilcox, D. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813456-6.00067-9 · Cited by 3
Self-citationHemophilia A in a litter of Border Collies caused by a one base pair deletion in the F8 gene
Brockmann, M., Mensing, N., von Luckner, J., Müller, E., & Kehl, A. (2023) · Veterinary Clinical Pathology · doi:10.1111/vcp.13312 · Cited by 1
Han, W., Huang, R., Li, B., Liu, L., Xu, W., & Zhang, G. (2023) · Scientific Reports · doi:10.1038/s41598-023-43649-y · Cited by 2
“Over the past few decades, the targeted expression of human FVIII in platelets has demonstrated therapeutic efficacy in mouse 17,18 , rat 19 , and dog 20 models of HA, without encountering issues of immunogenicity or thrombotic risks 21,22 .”
BackgroundLessons Learned from Animal Models of Inherited Bleeding Disorders.
Nichols, T. C. (2014) · PubMed · Cited by 1
Self-citationGen tedavisinin temel ilkeleri ve son gelişmeler
Rashnonejad, A., Durmaz, B., & Özkınay, F. (2014) · Ege Tıp Dergisi · doi:10.19161/etd.344096 · Cited by 10
Metadata
- Authors
- Du, L. M., Nurden, P., Nurden, A. T., Nichols, T. C., Bellinger, D. A., Jensen, E. S., Haberichter, S. L., Merricks, E., Raymer, R. A., Fang, J., Koukouritaki, S. B., Jacobi, P. M., Hawkins, T. B., Cornetta, K., Shi, Q., & Wilcox, D. A.
- Affiliations
- Children's Hospital of Wisconsin (US)
- Electrophysiology and Heart Modeling Institute (FR)
- University of North Carolina at Chapel Hill (US)
- Versiti Blood Center of Wisconsin (US)
- Indiana University Indianapolis (US)
- Corresponding author
- Wilcox, David A.
- ORCID
- Venue
- Nature Communications
- Published
- 2013-11-19
- Volume
- 4
- Issue
- 1
- Pages
- 2773-2773
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3868233
- OpenAlex
- W2039928766
- Cited by
- 119
- References
- 59
- Citations by year
- 2025: 5 · 2024: 4 · 2023: 11 · 2022: 11 · 2021: 9 · 2020: 9 · 2019: 6 · 2018: 9 · 2017: 7 · 2016: 14 · 2015: 21 · 2014: 11 · 2013: 2
- FWCI
- 11.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- UNC Libraries
- Funders
- American Heart Association
- Medical College of Wisconsin
- Children’s Hospital of Wisconsin Research Institute
- Children's Hospital Foundation
- Agence Nationale de la Recherche (ANR-08-GENO-028-03)
- Institut National de la Santé et de la Recherche Médicale (ANR-08-GENO-028-03)
- National Institutes of Health (HL-68138, HL63098)
- University of North Carolina at Chapel Hill
- National Heart, Lung, and Blood Institute (HL-102035, P40HL116242, HL 68138, R24HL063098, R01HL068138, HL-63 098, R01HL102035)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- hemophilia A, factor VIII, hemostasis, lentiviral vectors, platelet alpha-granules, factor VIII inhibitors, dogs, hemorrhage control
- MeSH terms
- Animals, Blood Platelets, Dog Diseases, Dogs, Factor VIII, Gene Expression Regulation, Hemophilia A, Hemostasis, Humans, Genetic Therapy, Integrin alpha2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.